<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of heart failure during pregnancy</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of heart failure during pregnancy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of heart failure during pregnancy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeanne M DeCara, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Roberto M Lang, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Melinda B Davis, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Wilson S Colucci, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles J Lockwood, MD, MHCM</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 09, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Pregnancy is associated with substantial hemodynamic changes, including 30 to 50 percent increases in both cardiac output and blood volume. In patients who are pregnant with a history of heart failure (HF) or other cardiovascular disorders, these demands can lead to clinical decompensation. In addition, patients without a history of cardiovascular disease can develop HF due to diseases acquired during pregnancy, such as peripartum cardiomyopathy. (See  <a class="medical medical_review" href="/d/html/443.html" rel="external">"Maternal adaptations to pregnancy: Cardiovascular and hemodynamic changes"</a> and  <a class="medical medical_review" href="/d/html/4945.html" rel="external">"Peripartum cardiomyopathy: Etiology, clinical manifestations, and diagnosis"</a>.)</p><p>In patients with HF who plan to become pregnant, are pregnant, or are breastfeeding, the medications used to treat HF must be adjusted to avoid toxicity to the fetus or infant. The evaluation and management of HF during pregnancy and breastfeeding will be reviewed here.</p><p>The general approach to pregnancy in patients with known congenital or acquired heart disease, treatment of peripartum cardiomyopathy, treatment of hypertrophic cardiomyopathy during pregnancy, and overviews of the management of acute and chronic HF are presented separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/8148.html" rel="external">"Acquired heart disease and pregnancy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1422.html" rel="external">"Pregnancy in women with congenital heart disease: General principles"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/95071.html" rel="external">"Peripartum cardiomyopathy: Treatment and prognosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3454.html" rel="external">"Treatment of acute decompensated heart failure: General considerations"</a>.)</p><p></p><p>Other causes of HF are discussed separately. (See  <a class="medical medical_review" href="/d/html/3485.html" rel="external">"Determining the etiology and severity of heart failure or cardiomyopathy"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>The nature of the initial evaluation in pregnant patients with (or at risk for) HF varies according to the setting. Risk assessment for maternal cardiovascular complications during pregnancy should utilize the modified World Health Organization classifications [<a href="#rid1">1</a>]. Stable as well as decompensated patients require joint cardiac and obstetric care, including baseline and follow-up maternal transthoracic echocardiograms as well as fetal ultrasound examinations [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Stable patient</span><span class="headingEndMark"> — </span>Patients with a history of HF or other cardiovascular disorders often present in a stable, well-compensated condition prior to or in the early stages of pregnancy. The initial approach to such patients involves assessing the cardiovascular risks associated with pregnancy and discussing these risks with the patient [<a href="#rid2">2</a>]. There are increased risks for both the mother and for the fetus and neonate (low birth weight/prematurity). (See  <a class="medical medical_review" href="/d/html/8148.html" rel="external">"Acquired heart disease and pregnancy", section on 'Assessing risk'</a> and  <a class="medical medical_review" href="/d/html/1422.html" rel="external">"Pregnancy in women with congenital heart disease: General principles", section on 'Preconception and prenatal care'</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">New or acute heart failure</span><span class="headingEndMark"> — </span>Patients with new or acute decompensated HF commonly present with progressive dyspnea, chest discomfort, or a range of other HF symptoms. The diagnosis is made using a constellation of clinical signs and symptoms and selected laboratory findings. The general approach to the diagnosis of new or acute decompensated HF is presented in detail separately. (See  <a class="medical medical_review" href="/d/html/3510.html" rel="external">"Heart failure: Clinical manifestations and diagnosis in adults"</a> and  <a class="medical medical_review" href="/d/html/3497.html" rel="external">"Approach to diagnosis and evaluation of acute decompensated heart failure in adults"</a>.)</p><p>The baseline or initial maternal cardiovascular evaluation usually includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span>A careful history (including review of medication list and any preexisting cardiovascular disease or risk factors) and physical examination with consideration of physiologic changes during pregnancy. Findings such as mild pedal edema may be observed during uncomplicated pregnancy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Assessment of New York Heart Association functional class  (<a class="graphic graphic_table graphicRef52683" href="/d/graphic/52683.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An electrocardiogram (ECG), which may reveal left ventricular (LV) or right ventricular (RV) hypertrophy, left atrial abnormalities, myocardial ischemia, or atrial fibrillation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Echocardiography if not recently performed or if there is concern for symptoms or signs of HF, including elevated B-type natriuretic peptides (BNP) or N-terminal pro-BNP (NT-proBNP) (see below).</p><p></p><p class="bulletIndent1">Echocardiography may reveal previously undetected structural heart disease (eg, valve abnormalities or congenital heart disease) or worsening LV function.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Laboratory tests, including a complete blood count, electrolytes, and renal function tests. Plasma BNP or NT-proBNP level is important for baseline risk stratification and can be used during pregnancy to differentiate HF symptoms from those of normal pregnancy [<a href="#rid3">3</a>]. In patients with HF, we also recommend BNP or NT-proBNP testing each trimester, after delivery, before hospital discharge, within a few weeks of parturition, and at the time of any clinical concern for worsening HF [<a href="#rid4">4</a>]. If there is concern for ischemia, cardiac troponin levels should be drawn. (See  <a class="medical medical_review" href="/d/html/3497.html" rel="external">"Approach to diagnosis and evaluation of acute decompensated heart failure in adults", section on 'Diagnostic evaluation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In select cases, cardiovascular magnetic resonance imaging or other cardiac imaging studies may be required (eg, congenital heart disease with RV dilation/dysfunction). The use of gadolinium contrast should be avoided during pregnancy. (See  <a class="medical medical_review" href="/d/html/4791.html" rel="external">"Diagnostic imaging in pregnant and lactating patients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A chest radiograph may not be necessary to establish the diagnosis of HF if there is clear clinical evidence of pulmonary edema; however, a radiograph should be performed when needed due to the low risk of fetal radiation [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/d/html/4791.html" rel="external">"Diagnostic imaging in pregnant and lactating patients"</a> and  <a class="medical medical_review" href="/d/html/3497.html" rel="external">"Approach to diagnosis and evaluation of acute decompensated heart failure in adults", section on 'Chest radiograph'</a>.)</p><p></p><p class="headingAnchor" id="H6"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis for HF symptoms during pregnancy or in the peripartum period includes the following conditions:</p><p class="bulletIndent1"><span class="glyph">●</span>Uncomplicated pregnancy is commonly accompanied by breathlessness, easy fatigability, decreased exercise tolerance, and peripheral edema. Physical examination (elevated jugular venous pressure and persistent rales) and laboratory findings (eg, elevated BNP and/or NT-proBNP levels, evidence of elevated intracardiac pressures, and systolic and/or diastolic dysfunction on echocardiography) distinguish benign symptoms and signs of normal pregnancy from HF. (See  <a class="medical medical_review" href="/d/html/443.html" rel="external">"Maternal adaptations to pregnancy: Cardiovascular and hemodynamic changes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary edema due to preeclampsia/eclampsia (hypertension plus proteinuria or other characteristic findings) may be present. (See  <a class="medical medical_review" href="/d/html/1599.html" rel="external">"Acute respiratory failure during pregnancy and the peripartum period", section on 'Pulmonary edema'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Amniotic fluid embolism is suggested by abrupt onset of hypotension, hypoxemia, disseminated intravascular coagulation, and coma or seizures. (See  <a class="medical medical_review" href="/d/html/1591.html" rel="external">"Amniotic fluid embolism"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary embolism may be distinguished from HF by physical examination, chest radiograph, and computed tomographic imaging. Of note, acute large pulmonary embolus can cause elevations in BNP or NT-proBNP (similar to levels seen with HF) and a dilated hypokinetic RV on echocardiogram. (See  <a class="medical medical_review" href="/d/html/8261.html" rel="external">"Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism"</a> and  <a class="medical medical_review" href="/d/html/1599.html" rel="external">"Acute respiratory failure during pregnancy and the peripartum period", section on 'Pulmonary embolism'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pneumonia is suggested by clinical history and physical examination. If a pregnant or postpartum patient has signs and symptoms of HF, a chest radiograph interpreted as pneumonia should be questioned. Echocardiography and BNP should be assessed if there is concern for pulmonary edema. (See  <a class="medical medical_review" href="/d/html/1599.html" rel="external">"Acute respiratory failure during pregnancy and the peripartum period", section on 'Pneumonia'</a> and  <a class="medical medical_review" href="/d/html/7032.html" rel="external">"Clinical evaluation and diagnostic testing for community-acquired pneumonia in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Myocardial infarction is diagnosed based upon ischemic symptoms, characteristic ECG abnormalities, and elevations in cardiac biomarkers. (See  <a class="medical medical_review" href="/d/html/89.html" rel="external">"Acute myocardial infarction and pregnancy"</a> and  <a class="medical medical_review" href="/d/html/52.html" rel="external">"Diagnosis of acute myocardial infarction"</a>.)</p><p></p><p class="headingAnchor" id="H462747090"><span class="h1">COUNSELING</span><span class="headingEndMark"> — </span>Management of a woman with HF (or at risk for HF) contemplating pregnancy includes counseling the patient regarding the expected prognosis and potential risks of pregnancy. The discussion should be based upon an individualized assessment of risk. Counseling should ideally occur prior to pregnancy by a team with expertise in cardio-obstetrics.</p><p>Specifically, patients with a preexisting dilated cardiomyopathy should be informed about the risk of deterioration during and after pregnancy, which is dependent upon the severity of systolic dysfunction [<a href="#rid1">1,4</a>]. Since the risk of maternal morbidity and mortality is high during pregnancy for patients with dilated cardiomyopathy with LVEF &lt;30 percent, avoidance of pregnancy is advised.</p><p>For those patients at very high risk who become pregnant, termination of pregnancy should be discussed with the patient and reliable contraception should be offered, noting there are no cardiovascular contraindications to most forms of birth control [<a href="#rid1">1,6-8</a>].</p><p>Discussion of prognosis with patients with peripartum cardiomyopathy is discussed separately. (See  <a class="medical medical_review" href="/d/html/95071.html" rel="external">"Peripartum cardiomyopathy: Treatment and prognosis", section on 'OUTCOMES'</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">MANAGEMENT GOALS</span><span class="headingEndMark"> — </span>Management goals for pregnant patients with HF and for patients with HF contemplating pregnancy are similar to those in nonpregnant patients. These include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Relief of symptoms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Optimizing hemodynamic status. (See  <a class="medical medical_review" href="/d/html/1593.html" rel="external">"Pulmonary artery catheterization: Indications, contraindications, and complications in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When possible, continuation (or initiation) of chronic therapies that improve long-term outcomes (including mortality) in patients with chronic cardiovascular disorders (eg, beta blocker therapy to treat HF with reduced ejection fraction and antihypertensive therapy in patients with hypertension).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment of precipitating factors (eg, anemia, arrhythmias, infection, thyroid disorders).</p><p></p><p>General discussions of the treatment of acute and chronic HF are presented separately. (See  <a class="medical medical_review" href="/d/html/3454.html" rel="external">"Treatment of acute decompensated heart failure: General considerations"</a> and  <a class="medical medical_review" href="/d/html/121085.html" rel="external">"Overview of the management of heart failure with reduced ejection fraction in adults"</a>.)</p><p class="headingAnchor" id="H134212866"><span class="h1">TREATMENT REGIMENS</span></p><p class="headingAnchor" id="H134212873"><span class="h2">Chronic heart failure</span><span class="headingEndMark"> — </span>Components of therapy for chronic HF include lifestyle modification, review of drugs, vaccinations (pneumococcal, coronavirus 2019, and annual influenza), pharmacologic therapy, and device therapy (including cardiac resynchronization therapy and/or implantable cardioverter-defibrillator therapy).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>HFrEF</strong> – Drugs used to treat chronic HF with reduced ejection fraction (HFrEF) during pregnancy include diuretics, beta blockers, <a class="drug drug_general" data-topicid="8528" href="/d/drug information/8528.html" rel="external">hydralazine</a> plus nitrate, and <a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">digoxin</a>. (See <a class="local">'Drugs'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>During pregnancy, clinical HF including pulmonary congestion is treated with a diuretic. (See <a class="local">'Diuretics'</a> below and  <a class="medical medical_review" href="/d/html/3512.html" rel="external">"Use of diuretics in patients with heart failure"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Beta blockers are generally continued during pregnancy in patients with chronic HFrEF who are taking a beta blocker as part of a chronic regimen to improve long-term outcomes. (See <a class="local">'Beta blockers'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For pregnant patients with symptoms of HF, <a class="drug drug_general" data-topicid="8528" href="/d/drug information/8528.html" rel="external">hydralazine</a> plus <a class="drug drug_general" data-topicid="8580" href="/d/drug information/8580.html" rel="external">isosorbide dinitrate</a> is a reasonable alternative to vasodilators contraindicated in pregnancy. (See <a class="local">'Vasodilators'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For pregnant patients with symptoms of HF due to systolic dysfunction that persist despite diuresis and vasodilator therapy, <a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">digoxin</a> can be used to treat symptoms. (See <a class="local">'Digoxin'</a> below.)</p><p></p><p class="bulletIndent1">We avoid the following agents due known toxicities and effects or the absence of safety data:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, and <a class="drug drug_general" data-topicid="102505" href="/d/drug information/102505.html" rel="external">sacubitril-valsartan</a> are contraindicated. (See <a class="local">'Avoid angiotensin inhibition'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We avoid mineralocorticoid receptor antagonists. (See <a class="local">'Aldosterone antagonists'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We avoid sodium-glucose co-transporter 2 (SGLT2) inhibitors during pregnancy given the absence of human safety data supporting use during pregnancy. (See <a class="local">'Sodium-glucose co-transporter 2 inhibitors'</a> below.)</p><p></p><p class="bulletIndent1">If indicated, implantation procedures for cardiac resynchronization therapy or implantable cardioverter-defibrillator therapy are performed prior to or following pregnancy, if possible, to avoid the risk of radiation to the fetus. (See  <a class="medical medical_review" href="/d/html/4791.html" rel="external">"Diagnostic imaging in pregnant and lactating patients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>HFpEF</strong> – For the treatment of HF with preserved ejection fraction (HFpEF), we avoid the use of mineralocorticoid receptor antagonists, <a class="drug drug_general" data-topicid="102505" href="/d/drug information/102505.html" rel="external">sacubitril-valsartan</a>, and SGLT2 inhibitors. (See <a class="local">'Aldosterone antagonists'</a> below and <a class="local">'Sodium-glucose co-transporter 2 inhibitors'</a> below and <a class="local">'Avoid angiotensin inhibition'</a> below.)</p><p></p><p class="headingAnchor" id="H134212886"><span class="h2">Acute heart failure</span><span class="headingEndMark"> — </span>Components of therapy for acute HF include supplemental oxygen therapy and pharmacologic therapy (including diuretic therapy in patients with clinical HF including those with pulmonary edema). (See  <a class="medical medical_review" href="/d/html/3450.html" rel="external">"Treatment of acute decompensated heart failure: Specific therapies"</a>.)</p><p>Pregnant patients with severe decompensated HFrEF and hypotension may require intravenous inotropic therapy. (See <a class="local">'Inotropes'</a> below and  <a class="medical medical_review" href="/d/html/3488.html" rel="external">"Inotropic agents in heart failure with reduced ejection fraction"</a>.)</p><p>For pregnant patients hospitalized with severe decompensated HF in whom further afterload reduction may be beneficial, options for therapy include intravenous <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a>, <a class="drug drug_general" data-topicid="8528" href="/d/drug information/8528.html" rel="external">hydralazine</a>, and sodium <a class="drug drug_general" data-topicid="9707" href="/d/drug information/9707.html" rel="external">nitroprusside</a>. If nitroprusside is selected for therapy, we measure thiocyanate levels to mitigate maternal and fetal toxicity, though levels that cause toxicity are ill-defined in adults and in the fetus. Further details on the use of these agents in acute decompensated HF can be found separately. (See <a class="local">'Vasodilators'</a> below and  <a class="medical medical_review" href="/d/html/3450.html" rel="external">"Treatment of acute decompensated heart failure: Specific therapies", section on 'Vasodilator therapy'</a>.)</p><p>Beta blocker therapy in pregnant patients with acute decompensated HFrEF is managed in the same manner as in nonpregnant patients with decompensated HFrEF. Beta blockers are not initiated in the setting of acute decompensated HFrEF. Similarly, patients on chronic beta blocker therapy who develop acute decompensated HFrEF often have the dose reduced or therapy withheld during initial treatment. (See <a class="local">'Beta blockers'</a> below and  <a class="medical medical_review" href="/d/html/3454.html" rel="external">"Treatment of acute decompensated heart failure: General considerations"</a>.)</p><p class="headingAnchor" id="H134212919"><span class="h2">Refractory heart failure</span><span class="headingEndMark"> — </span>For patients with acute or chronic HF that is refractory to treatment, specialized strategies include intravenous inotropic therapy and temporary mechanical circulatory support. (See  <a class="medical medical_review" href="/d/html/3495.html" rel="external">"Management of refractory heart failure with reduced ejection fraction"</a>.)</p><p>Limited experience with pregnancy and delivery in patients with LV assist devices has been described [<a href="#rid9">9,10</a>]. Concerns include maternal and fetal risks such as thromboembolism and the need for anticoagulation and the risk of bleeding exacerbated by the occurrence of acquired von Willebrand syndrome.</p><p class="headingAnchor" id="H1556663529"><span class="h1">DRUGS</span><span class="headingEndMark"> — </span>Due to the unique issues related to pregnancy and lactation, each medication to treat HF must be carefully considered in these clinical settings [<a href="#rid11">11</a>]. Since there are changes in the volume of distribution and glomerular filtration rate during pregnancy, dosing of certain medications may need to be increased during pregnancy.</p><p>The following discussion addresses the role of medications commonly used for the treatment of HF during pregnancy and lactation.</p><p class="headingAnchor" id="H8"><span class="h2">Avoid angiotensin inhibition</span><span class="headingEndMark"> — </span>Angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and <a class="drug drug_general" data-topicid="102505" href="/d/drug information/102505.html" rel="external">sacubitril-valsartan</a>, which are part of the standard long-term therapeutic regimen in nonpregnant patients with HF with reduced ejection fraction (HFrEF), are <strong>contraindicated</strong> during pregnancy. These drugs are associated with a high risk of adverse effects in the fetus during all trimesters of pregnancy, particularly the second and third trimesters. Consequences include fetal renal failure and even neonatal death [<a href="#rid12">12-15</a>]. (See  <a class="medical medical_review" href="/d/html/4789.html" rel="external">"Adverse effects of angiotensin converting enzyme inhibitors and receptor blockers in pregnancy"</a>.)</p><p>During preconception consultation, the risks of stopping HF medications should be addressed. If a patient plans to become pregnant, we will typically stop any ACE inhibitor, ARB, or angiotensin receptor-neprilysin inhibitor (ARNI), and repeat echocardiography (in some cases also with stress testing or strain imaging) to determine whether LV dilation or function has worsened. If this occurs or the clinical status worsens, the risks of pregnancy should be readdressed.</p><p>If an ACE inhibitor, ARB, or ARNI is inadvertently taken during the first trimester, immediate discontinuation of the medication and periodic fetal monitoring are required [<a href="#rid6">6</a>].</p><p>Levels in breast milk of ACE inhibitors are low and not expected to cause adverse effects in breastfed infants [<a href="#rid16">16</a>]. An ACE inhibitor that has been studied in breast milk or breastfed infants (such as <a class="drug drug_general" data-topicid="9405" href="/d/drug information/9405.html" rel="external">enalapril</a>, <a class="drug drug_general" data-topicid="9196" href="/d/drug information/9196.html" rel="external">captopril</a>, <a class="drug drug_general" data-topicid="9843" href="/d/drug information/9843.html" rel="external">quinapril</a>, or <a class="drug drug_general" data-topicid="9081" href="/d/drug information/9081.html" rel="external">benazepril</a>) is preferred [<a href="#rid17">17</a>]. There are no data on ARB or ARNI safety during breastfeeding, and therefore we do not recommend using an ARB or ARNI during breastfeeding. (See  <a class="medical medical_review" href="/d/html/6815.html" rel="external">"Treatment of hypertension in pregnant and postpartum patients", section on 'Drug options during breastfeeding'</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Beta blockers</span><span class="headingEndMark"> — </span>Beta-adrenergic blocking agents, such as extended-release <a class="drug drug_general" data-topicid="9645" href="/d/drug information/9645.html" rel="external">metoprolol</a>, <a class="drug drug_general" data-topicid="9208" href="/d/drug information/9208.html" rel="external">carvedilol</a>, and <a class="drug drug_general" data-topicid="9158" href="/d/drug information/9158.html" rel="external">bisoprolol</a>, are important components of the treatment regimen for patients with chronic HF due to systolic dysfunction.</p><p class="headingAnchor" id="H884662684"><span class="h3">During pregnancy</span><span class="headingEndMark"> — </span>Beta blockers are used frequently in pregnancy for the treatment of hypertension, arrhythmias, and other cardiac conditions. These agents are generally safe and effective during pregnancy, although there may be an increased risk of fetal growth restriction when they are administered [<a href="#rid18">18,19</a>]. In general, agents that are beta-1 selective (eg, <a class="drug drug_general" data-topicid="9645" href="/d/drug information/9645.html" rel="external">metoprolol</a>) are preferable, since these agents are less likely to interfere with beta-2 mediated uterine relaxation and peripheral vasodilation. However, <a class="drug drug_general" data-topicid="8940" href="/d/drug information/8940.html" rel="external">atenolol</a> should not be used during pregnancy since its use is associated with fetal growth restriction [<a href="#rid20">20</a>].</p><p>Continuation of chronic beta blocker therapy in stable patients with HFrEF who are pregnant is suggested. Fetal growth should be monitored by ultrasound. Beta blockers are not associated with an increased risk of congenital anomalies, although occasional cases of neonatal bradycardia and hypoglycemia have been reported.</p><p>Beta blockers are not initiated in the setting of acute decompensated HFrEF. Similarly, patients on chronic beta blocker therapy who develop acute decompensated HFrEF often have the dose reduced or therapy withheld during initial treatment. Once the patient with an episode of acute decompensation has stabilized, chronic beta blocker therapy may be initiated. (See  <a class="medical medical_review" href="/d/html/3454.html" rel="external">"Treatment of acute decompensated heart failure: General considerations"</a>.)</p><p class="headingAnchor" id="H884662691"><span class="h3">During nursing</span><span class="headingEndMark"> — </span>The excretion of beta blockers into breast milk appears to be higher for drugs with low protein binding. Risk of accumulation of beta blocker in infants rises with degree of renal excretion. Despite these variations, the amount of beta blocker that would be ingested by a nursing infant is generally small and measured serum beta blocker levels in breastfed infants have generally been very low or undetectable, with limited exceptions (eg, <a class="drug drug_general" data-topicid="8940" href="/d/drug information/8940.html" rel="external">atenolol</a>) [<a href="#rid16">16,21</a>].</p><p>Among the three beta blockers recommended to treat stable HFrEF, we suggest use of <a class="drug drug_general" data-topicid="9645" href="/d/drug information/9645.html" rel="external">metoprolol</a> in nursing mothers, based upon the following considerations:</p><p class="bulletIndent1"><span class="glyph">●</span>Though <a class="drug drug_general" data-topicid="9645" href="/d/drug information/9645.html" rel="external">metoprolol</a> (which is 10 percent protein bound and 40 percent renally excreted) is excreted into breast milk, breastfed infants have had very low or undetectable serum levels [<a href="#rid16">16,21</a>]. Limited studies on the use of metoprolol during breastfeeding have reported no adverse reactions in breastfed infants.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Since <a class="drug drug_general" data-topicid="9208" href="/d/drug information/9208.html" rel="external">carvedilol</a> is highly protein bound (95 percent) and has low renal excretion (1 percent), carvedilol likely presents a low risk for accumulation in breastfed infants [<a href="#rid16">16</a>]. In patients with hypertension or on stable doses of carvedilol, it may be reasonable to use carvedilol despite less published experience than <a class="drug drug_general" data-topicid="9645" href="/d/drug information/9645.html" rel="external">metoprolol</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Since <a class="drug drug_general" data-topicid="9158" href="/d/drug information/9158.html" rel="external">bisoprolol</a> has relatively low protein binding (30 percent) and moderately high renal excretion (50 percent), it presents a moderately high risk for accumulation in breastfed infants [<a href="#rid16">16</a>]. Since there is little published experience with bisoprolol during breastfeeding, other agents may be preferred when nursing a newborn or preterm infant.</p><p></p><p>We avoid <a class="drug drug_general" data-topicid="8940" href="/d/drug information/8940.html" rel="external">atenolol</a> with lactation, as other agents are preferred.</p><p class="headingAnchor" id="H1057900551"><span class="h2">Aldosterone antagonists</span><span class="headingEndMark"> — </span>The aldosterone antagonists <a class="drug drug_general" data-topicid="9943" href="/d/drug information/9943.html" rel="external">spironolactone</a> and <a class="drug drug_general" data-topicid="8789" href="/d/drug information/8789.html" rel="external">eplerenone</a>, which compete with aldosterone for the mineralocorticoid receptor, prolong survival in selected patients with HF. However, in animal studies, the antiandrogen effects of spironolactone caused feminization of the male fetus [<a href="#rid22">22,23</a>]. There are neither data nor clinical experience to support the safety of these agents during pregnancy. Thus, we suggest that these agents <strong>not</strong> be used during pregnancy.</p><p>Limited data suggest that <a class="drug drug_general" data-topicid="9943" href="/d/drug information/9943.html" rel="external">spironolactone</a> use is acceptable during breastfeeding since the maternal diuretic effect is unlikely to be potent enough to affect lactation, and the dose to the breastfeeding infant is low [<a href="#rid16">16</a>]. In patients with HF who are breastfeeding, we generally avoid <a class="drug drug_general" data-topicid="8789" href="/d/drug information/8789.html" rel="external">eplerenone</a> due to lack of data.</p><p class="headingAnchor" id="H3818817525"><span class="h2">Sodium-glucose co-transporter 2 inhibitors</span></p><p class="headingAnchor" id="H4200023953"><span class="h3">During pregnancy</span><span class="headingEndMark"> — </span>Sodium-glucose co-transporter 2 (SGLT2) inhibitors should be avoided during pregnancy. There are inadequate safety data in pregnant patients to determine the drug-associated risk for major birth defects or miscarriage. Based on animal studies, adverse effects on renal development may be seen in a timeline that correlates with the second and third trimesters of human pregnancy.</p><p class="headingAnchor" id="H3189233767"><span class="h3">During nursing</span><span class="headingEndMark"> — </span>The SGLT2 inhibitors <a class="drug drug_general" data-topicid="93383" href="/d/drug information/93383.html" rel="external">dapagliflozin</a> and <a class="drug drug_general" data-topicid="96484" href="/d/drug information/96484.html" rel="external">empagliflozin</a> are uncharged molecules that are highly protein bound and unlikely to pass into breastmilk in clinically important amounts [<a href="#rid16">16</a>]. However, due to lack of published data, we do not recommend these medications while nursing a newborn or preterm infant.</p><p class="headingAnchor" id="H12"><span class="h2">Digoxin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">Digoxin</a> is generally considered safe in pregnancy, despite anecdotal reports of adverse effects [<a href="#rid24">24,25</a>]. Dosing may need to be increased to achieve a therapeutic effect during pregnancy. The decision to do so should be based upon the perceived adequacy of the therapeutic effect rather than purely on serum levels [<a href="#rid26">26</a>]. Transplacental passage of digoxin has been documented, and this pharmacokinetic property has been used for the in-utero treatment of fetal tachyarrhythmias [<a href="#rid27">27</a>].</p><p>During pregnancy, <a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">digoxin</a> can be particularly useful for two reasons:</p><p class="bulletIndent1"><span class="glyph">●</span>The use of conventional HF therapies is limited.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The increased physiologic demands of pregnancy can exacerbate HF symptoms.</p><p></p><p>Similar to nonpregnant patients, reasons to consider adding <a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">digoxin</a> in pregnant patients include:</p><p class="bulletIndent1"><span class="glyph">●</span>The persistence of symptoms (such as fatigue, dyspnea, and exercise intolerance) despite optimal treatment with agents safe for use during with pregnancy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For control of the ventricular rate in HF patients with atrial fibrillation who cannot achieve adequate control on beta blockers alone.</p><p></p><p class="headingAnchor" id="H2881804002"><span class="h3">During nursing</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">Digoxin</a> levels in breast milk are low; the dose to a breastfed infant is small and no adverse effects have been reported in newborns [<a href="#rid16">16</a>]. If an intravenous dose of digoxin is administered to a nursing mother, avoidance of breastfeeding for two hours will lessen the dose ingested by the infant.</p><p class="headingAnchor" id="H2973079137"><span class="h2">Ivabradine</span><span class="headingEndMark"> — </span>Given lack of evidence of safety during pregnancy and nursing, we suggest avoiding <a class="drug drug_general" data-topicid="101166" href="/d/drug information/101166.html" rel="external">ivabradine</a> use in pregnant or nursing patients.</p><p class="headingAnchor" id="H1629347577"><span class="h2">Vericiguat</span><span class="headingEndMark"> — </span>We do not use <a class="drug drug_general" data-topicid="130565" href="/d/drug information/130565.html" rel="external">vericiguat</a> in patients who are pregnant, who seek to become pregnant, or who are breastfeeding.</p><p class="headingAnchor" id="H13"><span class="h2">Diuretics</span><span class="headingEndMark"> — </span>Diuretics are given for HF during pregnancy for symptomatic relief of congestion, pulmonary edema (eg, paroxysmal nocturnal dyspnea or exertional dyspnea), or peripheral edema. For treatment of HF, loop diuretics are generally preferred over thiazide diuretics and potassium-sparing diuretics. (See  <a class="medical medical_review" href="/d/html/3512.html" rel="external">"Use of diuretics in patients with heart failure"</a>.)</p><p>Treatment with loop diuretics (without waiting for response to sodium restriction) is recommended for patients with any degree of pulmonary congestion. Potential maternal complications of loop diuretic use are similar to those of nonpregnant patients and include volume contraction, metabolic alkalosis, decreased carbohydrate tolerance, hypokalemia, hyponatremia, hyperuricemia, and pancreatitis. Potential risks to the fetus are related to the potential for intravascular volume contraction and reduced placental perfusion.</p><p>A thiazide diuretic may be added if volume cannot be adequately controlled with a loop diuretic alone. However, there are reports of bleeding disorders and hyponatremia among neonates of patients who have taken thiazide diuretics during pregnancy [<a href="#rid28">28</a>].</p><p>Volume contraction caused by diuretics might decrease lactation [<a href="#rid16">16</a>]. No information is available on the use of loop diuretics during breastfeeding. Moderate doses of thiazide diuretics (eg, up to 50 mg daily of <a class="drug drug_general" data-topicid="8529" href="/d/drug information/8529.html" rel="external">hydrochlorothiazide</a>) are acceptable during lactation.</p><p class="headingAnchor" id="H14"><span class="h2">Vasodilators</span><span class="headingEndMark"> — </span>Vasodilator therapy improves cardiac output in moderate to severe HF and slows the rate of myocardial deterioration at all stages by inducing afterload reduction.</p><p class="headingAnchor" id="H134212619"><span class="h3">Hydralazine plus nitrate</span><span class="headingEndMark"> — </span>Because ACE inhibitors, ARBs, and <a class="drug drug_general" data-topicid="102505" href="/d/drug information/102505.html" rel="external">sacubitril-valsartan</a> are contraindicated in pregnancy, the combination of <a class="drug drug_general" data-topicid="8528" href="/d/drug information/8528.html" rel="external">hydralazine</a> plus nitrate (<a class="drug drug_general" data-topicid="8580" href="/d/drug information/8580.html" rel="external">isosorbide dinitrate</a>) is the vasodilator therapy of choice during pregnancy. Hydralazine has been used for many years in the treatment of hypertension during pregnancy and appears to be safe for both the mother and fetus [<a href="#rid29">29-31</a>].</p><p>The combination of <a class="drug drug_general" data-topicid="8528" href="/d/drug information/8528.html" rel="external">hydralazine</a> plus nitrate (<a class="drug drug_general" data-topicid="8580" href="/d/drug information/8580.html" rel="external">isosorbide dinitrate</a>) is the vasodilator therapy of choice in pregnant patients with HF [<a href="#rid6">6,32</a>]. The evidence for hydralazine plus nitrate therapy for HFrEF is not as strong as the evidence for ACE inhibitor therapy. Therefore, we suggest that hydralazine not be routinely started when ACE inhibitor, ARB, or ARNI therapy is discontinued in patients who are clinically stable and normotensive. Hydralazine plus nitrate therapy should be used instead of ACE inhibitors, ARBs, or ARNI in pregnant patients with HF who are hypertensive, have severe LV systolic dysfunction, or have evidence of congestion and decompensated HF.</p><p>Limited data on breast milk and breastfed infant serum levels suggest that use of <a class="drug drug_general" data-topicid="8528" href="/d/drug information/8528.html" rel="external">hydralazine</a> is acceptable in nursing mothers [<a href="#rid16">16</a>]. Evidence is lacking on use of <a class="drug drug_general" data-topicid="8580" href="/d/drug information/8580.html" rel="external">isosorbide dinitrate</a> during breastfeeding. Since we usually restart ACE inhibitor therapy postpartum, we seldom use hydralazine plus nitrate to treat HF in nursing mothers.</p><p class="headingAnchor" id="H134212625"><span class="h3">Intravenous agents</span><span class="headingEndMark"> — </span>A separate issue is the use of intravenous vasodilators (eg, <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a> and <a class="drug drug_general" data-topicid="9707" href="/d/drug information/9707.html" rel="external">nitroprusside</a>) in pregnant patients with decompensated HF, particularly if associated with hypertension. Intravenous afterload reduction should be undertaken with great care in this setting given the risk of deterioration of the fetal heart rate with rapid and profound drop in maternal blood pressure. Continuous fetal monitoring is recommended if viability has been achieved.</p><p class="headingAnchor" id="H134212689"><span class="h4">Nitroglycerin or nitroprusside</span><span class="headingEndMark"> — </span>In pregnant patients with decompensated HF, particularly those with hypertension, cautious use of intravenous <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a> can be attempted [<a href="#rid33">33</a>]. However, <a class="drug drug_general" data-topicid="9707" href="/d/drug information/9707.html" rel="external">nitroprusside</a> should be used only when all other interventions have failed and when it is essential for maternal well–being. Even under these conditions, the dose and duration of therapy should be minimized due to the metabolism of this agent to thiocyanate and cyanide, which has resulted in fetal cyanide poisoning in animal models [<a href="#rid34">34</a>]. Experience with nitroglycerin and nitroprusside in pregnant patients comes largely from treatment of hypertensive emergencies. (See  <a class="medical medical_review" href="/d/html/3840.html" rel="external">"Drugs used for the treatment of hypertensive emergencies", section on 'Nitroprusside'</a> and  <a class="medical medical_review" href="/d/html/6815.html" rel="external">"Treatment of hypertension in pregnant and postpartum patients", section on 'Nitroprusside'</a> and  <a class="medical medical_review" href="/d/html/3450.html" rel="external">"Treatment of acute decompensated heart failure: Specific therapies"</a>.)</p><p>Since thiocyanate is excreted into breast milk and cyanide may also enter breast milk, nursing should be avoided if <a class="drug drug_general" data-topicid="9707" href="/d/drug information/9707.html" rel="external">nitroprusside</a> therapy is required [<a href="#rid16">16</a>]. Since intravenous use of <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a> has not been studied during breastfeeding [<a href="#rid16">16</a>], nursing should be avoided when intravenous nitroglycerin is used.</p><p class="headingAnchor" id="H16"><span class="h2">Inotropes</span><span class="headingEndMark"> — </span>Patients with acute decompensated HF and systolic dysfunction who are hypotensive or who remain in pulmonary edema despite oxygen, diuresis, and, if tolerated, vasodilators, may benefit from intravenous inotropic support. As each of these medications has slightly different properties, in a seriously ill pregnant woman, the selection of a specific agent should be based upon the clinical scenario. (See  <a class="medical medical_review" href="/d/html/3488.html" rel="external">"Inotropic agents in heart failure with reduced ejection fraction"</a>.)</p><p><a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">Dobutamine</a> is a beta agonist with both inotropic and vasodilator properties. <a class="drug drug_general" data-topicid="9384" href="/d/drug information/9384.html" rel="external">Dopamine</a> has an inotropic effect and variable effects on the peripheral vasculature, depending upon the dose administered. Like dobutamine, the phosphodiesterase inhibitors such as <a class="drug drug_general" data-topicid="9652" href="/d/drug information/9652.html" rel="external">milrinone</a> have vasodilatory properties. Drugs with both inotropic and vasodilatory properties address the two hemodynamic problems that most commonly lead to low cardiac output in severe HF (ie, poor cardiac contractility, peripheral vasoconstriction).</p><p>No information is available on the use of <a class="drug drug_general" data-topicid="9384" href="/d/drug information/9384.html" rel="external">dopamine</a> or <a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">dobutamine</a> during breastfeeding [<a href="#rid16">16</a>]. Intravenous dopamine infusion may decrease milk production, but this has not been directly studied.</p><p class="headingAnchor" id="H17"><span class="h2">Vasopressors</span><span class="headingEndMark"> — </span>Vasopressors (eg, <a class="drug drug_general" data-topicid="9709" href="/d/drug information/9709.html" rel="external">norepinephrine</a> and <a class="drug drug_general" data-topicid="9768" href="/d/drug information/9768.html" rel="external">phenylephrine</a>) are usually avoided in patients with HF, since such patients usually have high systemic vascular resistance at baseline and further peripheral vasoconstriction may impair cardiac output. In pregnant patients, vasopressors carry the additional risk of impairing uterine blood flow. In critically ill, hypotensive patients, however, blood pressure may need to be supported. There are few data to guide selection of an appropriate vasopressor in a pregnant woman. Animal studies suggest that <a class="drug drug_general" data-topicid="9384" href="/d/drug information/9384.html" rel="external">dopamine</a> may have less deleterious effects on uterine blood flow than norepinephrine or phenylephrine. (See  <a class="medical medical_review" href="/d/html/1629.html" rel="external">"Critical illness during pregnancy and the peripartum period", section on 'Vasopressors'</a>.)</p><p>No information is available on the use of <a class="drug drug_general" data-topicid="9384" href="/d/drug information/9384.html" rel="external">dopamine</a>, <a class="drug drug_general" data-topicid="9709" href="/d/drug information/9709.html" rel="external">norepinephrine</a>, or <a class="drug drug_general" data-topicid="9768" href="/d/drug information/9768.html" rel="external">phenylephrine</a> during breastfeeding [<a href="#rid16">16</a>]. These drugs may decrease milk production.</p><p class="headingAnchor" id="H19"><span class="h2">Anticoagulants</span><span class="headingEndMark"> — </span>The role of anticoagulation to manage thromboemboli and thromboembolic risk in pregnant patients is described elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>Deep vein thrombosis. (See  <a class="medical medical_review" href="/d/html/1347.html" rel="external">"Venous thromboembolism in pregnancy: Prevention"</a> and  <a class="medical medical_review" href="/d/html/1350.html" rel="external">"Venous thromboembolism in pregnancy and postpartum: Treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>LV thrombus. (See  <a class="medical medical_review" href="/d/html/3502.html" rel="external">"Antithrombotic therapy in patients with heart failure"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Atrial fibrillation, atrial flutter, and other supraventricular tachycardias. (See  <a class="medical medical_review" href="/d/html/13600.html" rel="external">"Supraventricular arrhythmias during pregnancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Valve disease and prosthetic valves. (See  <a class="medical medical_review" href="/d/html/97124.html" rel="external">"Pregnancy and valve disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prophylactic anticoagulation in peripartum cardiomyopathy. (See  <a class="medical medical_review" href="/d/html/95071.html" rel="external">"Peripartum cardiomyopathy: Treatment and prognosis", section on 'Antithrombotic therapy'</a>.)</p><p></p><p class="headingAnchor" id="H1556664009"><span class="h1">DELIVERY</span><span class="headingEndMark"> — </span>Management of delivery in patients with heart disease is discussed separately. (See  <a class="medical medical_review" href="/d/html/8148.html" rel="external">"Acquired heart disease and pregnancy", section on 'Management of labor and delivery'</a>.)</p><p class="headingAnchor" id="H2629197644"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/118887.html" rel="external">"Society guideline links: Management of cardiovascular diseases during pregnancy"</a> and  <a class="medical medical_society_guidelines" href="/d/html/115372.html" rel="external">"Society guideline links: Heart failure in adults"</a>.)</p><p class="headingAnchor" id="H20"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation of heart failure during pregnancy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with a history of heart failure (HF) or cardiac disorders that put them at risk for HF should undergo a thorough initial evaluation prior to or in the early stage of pregnancy. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients who develop signs or symptoms of HF during pregnancy should undergo an initial evaluation similar to that generally recommended for patients with suspected HF. B-type natriuretic peptide (BNP) or N-terminal pro-BNP (NT-proBNP) levels should be measured in all patients with known or suspected HF, with a low threshold for echocardiography. (See <a class="local">'New or acute heart failure'</a> above and  <a class="medical medical_review" href="/d/html/3510.html" rel="external">"Heart failure: Clinical manifestations and diagnosis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Counseling</strong> – Management of a woman with HF (or at risk for HF) contemplating pregnancy includes counseling the patient regarding the expected prognosis and potential risks of pregnancy. The discussion should be based upon an individualized assessment of risk utilizing the modified World Health Organization classification of maternal cardiovascular risk. Counseling should ideally occur prior to pregnancy by an experienced cardio-obstetrics team. (See <a class="local">'Counseling'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment regimens</strong> – Patients with HF during pregnancy should be treated for HF, except for avoiding contraindicated medications such as angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), angiotensin receptor-neprilysin inhibitor (ARNI), aldosterone antagonists, <a class="drug drug_general" data-topicid="130565" href="/d/drug information/130565.html" rel="external">vericiguat</a>, and <a class="drug drug_general" data-topicid="101166" href="/d/drug information/101166.html" rel="external">ivabradine</a>. We also suggest avoiding use of sodium-glucose co-transporter 2 (SGLT2) inhibitors during pregnancy, given lack of evidence of safety during pregnancy. (See <a class="local">'Chronic heart failure'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Drugs used to treat chronic HF with reduced ejection fraction (HFrEF) during pregnancy include diuretics, beta blockers, <a class="drug drug_general" data-topicid="8528" href="/d/drug information/8528.html" rel="external">hydralazine</a> plus nitrate, and <a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">digoxin</a>. (See <a class="local">'Drugs'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>During pregnancy, clinical HF including pulmonary congestion is treated with a diuretic. (See <a class="local">'Diuretics'</a> above and  <a class="medical medical_review" href="/d/html/3512.html" rel="external">"Use of diuretics in patients with heart failure"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Beta blockers are generally continued during pregnancy in patients with chronic HFrEF who are taking a beta blocker as part of a chronic regimen to improve long-term outcomes. (See <a class="local">'Beta blockers'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For pregnant patients with symptoms of HF, <a class="drug drug_general" data-topicid="8528" href="/d/drug information/8528.html" rel="external">hydralazine</a> plus <a class="drug drug_general" data-topicid="8580" href="/d/drug information/8580.html" rel="external">isosorbide dinitrate</a> is a reasonable alternative to vasodilators contraindicated in pregnancy. (See <a class="local">'Vasodilators'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For pregnant patients with symptoms of HF due to systolic dysfunction that persist despite diuresis and vasodilator therapy, addition of <a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">digoxin</a> may be considered for treatment of symptoms. (See <a class="local">'Digoxin'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Acute decompensated HF during pregnancy is managed with supplemental oxygen therapy and pharmacologic therapy (including diuretic therapy in patients with clinical HF including those with pulmonary edema). (See <a class="local">'Acute heart failure'</a> above and  <a class="medical medical_review" href="/d/html/3450.html" rel="external">"Treatment of acute decompensated heart failure: Specific therapies"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Beta blocker therapy in pregnant patients with acute decompensated HFrEF is managed in the same manner as in nonpregnant patients with decompensated HF. (See <a class="local">'Beta blockers'</a> above and  <a class="medical medical_review" href="/d/html/3454.html" rel="external">"Treatment of acute decompensated heart failure: General considerations"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Pregnant patients with unstable, severe decompensated HFrEF and hypotension may require intravenous inotropic therapy. (See <a class="local">'Inotropes'</a> above and  <a class="medical medical_review" href="/d/html/3488.html" rel="external">"Inotropic agents in heart failure with reduced ejection fraction"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Treatment of HF with preserved ejection fraction (HFpEF) during pregnancy remains empiric and includes control of systolic and diastolic hypertension, control of pulmonary congestion and peripheral edema with diuretics, and control of heart rate if elevated.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Antihypertensive agents that may be used to treat HFpEF during pregnancy include beta blockers and heart rate limiting calcium channel blockers.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">Digoxin</a> is not indicated in patients with HFpEF.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with refractory HF, specialized strategies include intravenous inotropic therapy, mechanical circulatory support (eg, left ventricular [LV] assist device), and cardiac transplantation. Limited data are available on LV assist device use during pregnancy. Cardiac transplant recipients are generally advised to avoid pregnancy during the first year posttransplantation when the risk of rejection is greatest and immunosuppressive therapy most aggressive. (See  <a class="medical medical_review" href="/d/html/3529.html" rel="external">"Heart transplantation in adults: Pregnancy after transplantation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drugs to avoid during pregnancy</strong> –<strong> </strong>Drugs that should not be used in patients who are pregnant or who are planning to become pregnant include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>ACE inhibitors, ARBs, and <a class="drug drug_general" data-topicid="102505" href="/d/drug information/102505.html" rel="external">sacubitril-valsartan</a> (see <a class="local">'Avoid angiotensin inhibition'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>Mineralocorticoid receptor antagonists (see <a class="local">'Aldosterone antagonists'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span>SGLT2 inhibitors (see <a class="local">'Sodium-glucose co-transporter 2 inhibitors'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="101166" href="/d/drug information/101166.html" rel="external">Ivabradine</a> (see <a class="local">'Ivabradine'</a> above)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="130565" href="/d/drug information/130565.html" rel="external">Vericiguat</a> (see <a class="local">'Vericiguat'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anticoagulation</strong> – Indications for anticoagulation in patients with HF during pregnancy include standard indications for anticoagulation, such as evidence of systemic embolism or LV thrombus, presence of a mechanical prosthetic heart valve, and select cases of atrial fibrillation. (See <a class="local">'Anticoagulants'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J 2018; 39:3165.</a></li><li><a class="nounderline abstract_t">Davis MB, Arendt K, Bello NA, et al. Team-Based Care of Women With Cardiovascular Disease From Pre-Conception Through Pregnancy and Postpartum: JACC Focus Seminar 1/5. J Am Coll Cardiol 2021; 77:1763.</a></li><li><a class="nounderline abstract_t">Tanous D, Siu SC, Mason J, et al. B-type natriuretic peptide in pregnant women with heart disease. J Am Coll Cardiol 2010; 56:1247.</a></li><li><a class="nounderline abstract_t">Davis MB, Arany Z, McNamara DM, et al. Peripartum Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol 2020; 75:207.</a></li><li><a class="nounderline abstract_t">Bello NA, Bairey Merz CN, Brown H, et al. Diagnostic Cardiovascular Imaging and Therapeutic Strategies in Pregnancy: JACC Focus Seminar 4/5. J Am Coll Cardiol 2021; 77:1813.</a></li><li><a class="nounderline abstract_t">European Society of Gynecology (ESG), Association for European Paediatric Cardiology (AEPC), German Society for Gender Medicine (DGesGM), et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J 2011; 32:3147.</a></li><li><a class="nounderline abstract_t">Bauersachs J, Arrigo M, Hilfiker-Kleiner D, et al. Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail 2016; 18:1096.</a></li><li><a class="nounderline abstract_t">Lindley KJ, Bairey Merz CN, Davis MB, et al. Contraception and Reproductive Planning for Women With Cardiovascular Disease: JACC Focus Seminar 5/5. J Am Coll Cardiol 2021; 77:1823.</a></li><li><a class="nounderline abstract_t">Sims DB, Vink J, Uriel N, et al. A successful pregnancy during mechanical circulatory device support. J Heart Lung Transplant 2011; 30:1065.</a></li><li><a class="nounderline abstract_t">Meece LE, Park K, Wen TS, et al. Pregnancy With a Ventricular Assist Device: A Systematic Review of the Existing Literature. J Card Fail 2021; 27:185.</a></li><li><a class="nounderline abstract_t">Lee W. Clinical management of gravid women with peripartum cardiomyopathy. Obstet Gynecol Clin North Am 1991; 18:257.</a></li><li><a class="nounderline abstract_t">Alwan S, Polifka JE, Friedman JM. Angiotensin II receptor antagonist treatment during pregnancy. Birth Defects Res A Clin Mol Teratol 2005; 73:123.</a></li><li><a class="nounderline abstract_t">Lavoratti G, Seracini D, Fiorini P, et al. Neonatal anuria by ACE inhibitors during pregnancy. Nephron 1997; 76:235.</a></li><li><a class="nounderline abstract_t">Bowen ME, Ray WA, Arbogast PG, et al. Increasing exposure to angiotensin-converting enzyme inhibitors in pregnancy. Am J Obstet Gynecol 2008; 198:291.e1.</a></li><li><a class="nounderline abstract_t">Buawangpong N, Teekachunhatean S, Koonrungsesomboon N. Adverse pregnancy outcomes associated with first-trimester exposure to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers: A systematic review and meta-analysis. Pharmacol Res Perspect 2020; 8:e00644.</a></li><li class="breakAll">http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACTMED (Accessed on February 01, 2023).</li><li><a class="nounderline abstract_t">American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001; 108:776.</a></li><li><a class="nounderline abstract_t">Ruys TP, Maggioni A, Johnson MR, et al. Cardiac medication during pregnancy, data from the ROPAC. Int J Cardiol 2014; 177:124.</a></li><li><a class="nounderline abstract_t">Abalos E, Duley L, Steyn DW, Gialdini C. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2018; 10:CD002252.</a></li><li><a class="nounderline abstract_t">Lydakis C, Lip GY, Beevers M, Beevers DG. Atenolol and fetal growth in pregnancies complicated by hypertension. Am J Hypertens 1999; 12:541.</a></li><li><a class="nounderline abstract_t">Beardmore KS, Morris JM, Gallery ED. Excretion of antihypertensive medication into human breast milk: a systematic review. Hypertens Pregnancy 2002; 21:85.</a></li><li><a class="nounderline abstract_t">Jaussan V, Lemarchand-Béraud T, Gómez F. Modifications of the gonadal function in the adult rat after fetal exposure to spironolactone. Biol Reprod 1985; 32:1051.</a></li><li><a class="nounderline abstract_t">Hecker A, Hasan SH, Neumann F. Disturbances in sexual differentiation of rat foetuses following spironolactone treatment. Acta Endocrinol (Copenh) 1980; 95:540.</a></li><li><a class="nounderline abstract_t">Joglar JA, Page RL. Treatment of cardiac arrhythmias during pregnancy: safety considerations. Drug Saf 1999; 20:85.</a></li><li><a class="nounderline abstract_t">Widerhorn J, Rubin JN, Frishman WH, Elkayam U. Cardiovascular drugs in pregnancy. Cardiol Clin 1987; 5:651.</a></li><li><a class="nounderline abstract_t">Lees KR, Rubin PC. Treatment of cardiovascular diseases. Br Med J (Clin Res Ed) 1987; 294:358.</a></li><li><a class="nounderline abstract_t">King CR, Mattioli L, Goertz KK, Snodgrass W. Successful treatment of fetal supraventricular tachycardia with maternal digoxin therapy. Chest 1984; 85:573.</a></li><li><a class="nounderline abstract_t">Lindheimer MD, Katz AI. Sodium and diuretics in pregnancy. N Engl J Med 1973; 288:891.</a></li><li class="breakAll">Lang RM, Borow KM. Heart disease. In: Medical Disorders During Pregnancy, 3rd ed, Barron WM, Lindheimer MD (Eds), Mosby Inc, St. Louis 2000. p.180.</li><li><a class="nounderline abstract_t">Vink GJ, Moodley J, Philpott RH. Effect of dihydralazine on the fetus in the treatment of maternal hypertension. Obstet Gynecol 1980; 55:519.</a></li><li><a class="nounderline abstract_t">Kuzniar J, Skret A, Piela A, et al. Hemodynamic effects of intravenous hydralazine in pregnant women with severe hypertension. Obstet Gynecol 1985; 66:453.</a></li><li><a class="nounderline abstract_t">Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail 2010; 12:767.</a></li><li class="breakAll">Hall JB, Schmidt GA. Critical illness. In: Medical Disorders During Pregnancy, Barron WM, Lindheimer MD (Eds), Mosby Inc, St. Louis 2000. p.240.</li><li><a class="nounderline abstract_t">Palmer RF, Lasseter KC. Drug therapy. Sodium nitroprusside. N Engl J Med 1975; 292:294.</a></li></ol></div><div id="topicVersionRevision">Topic 3507 Version 25.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30165544" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33832604" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Team-Based Care of Women With Cardiovascular Disease From Pre-Conception Through Pregnancy and Postpartum: JACC Focus Seminar 1/5.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20883932" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : B-type natriuretic peptide in pregnant women with heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31948651" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Peripartum Cardiomyopathy: JACC State-of-the-Art Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33832607" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Diagnostic Cardiovascular Imaging and Therapeutic Strategies in Pregnancy: JACC Focus Seminar 4/5.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21873418" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27338866" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33832608" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Contraception and Reproductive Planning for Women With Cardiovascular Disease: JACC Focus Seminar 5/5.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21752670" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A successful pregnancy during mechanical circulatory device support.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33573759" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Pregnancy With a Ventricular Assist Device: A Systematic Review of the Existing Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1945254" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Clinical management of gravid women with peripartum cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15669052" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Angiotensin II receptor antagonist treatment during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9200422" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Neonatal anuria by ACE inhibitors during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18191803" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Increasing exposure to angiotensin-converting enzyme inhibitors in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32815286" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Adverse pregnancy outcomes associated with first-trimester exposure to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32815286" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Adverse pregnancy outcomes associated with first-trimester exposure to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11533352" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Transfer of drugs and other chemicals into human milk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25499355" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Cardiac medication during pregnancy, data from the ROPAC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30277556" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Antihypertensive drug therapy for mild to moderate hypertension during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10371362" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Atenolol and fetal growth in pregnancies complicated by hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12044345" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Excretion of antihypertensive medication into human breast milk: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3926011" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Modifications of the gonadal function in the adult rat after fetal exposure to spironolactone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7456979" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Disturbances in sexual differentiation of rat foetuses following spironolactone treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9935279" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Treatment of cardiac arrhythmias during pregnancy: safety considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2900070" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Cardiovascular drugs in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2880619" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Treatment of cardiovascular diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6368144" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Successful treatment of fetal supraventricular tachycardia with maternal digoxin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4571247" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Sodium and diuretics in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4571247" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Sodium and diuretics in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7366909" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Effect of dihydralazine on the fetus in the treatment of maternal hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4047535" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Hemodynamic effects of intravenous hydralazine in pregnant women with severe hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20675664" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20675664" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1089194" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Drug therapy. Sodium nitroprusside.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
